Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine ...
BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (GLUE) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, ...
Hello, everyone, and thank you for joining us for Marti's First Half 2024 Conference Call. Before we begin, I'd like to mention that today's presentation and earnings release are available on Marti's ...
Marti Technologies, Inc. (AMEX: MRT) Q2 2024 Earnings Call Transcript September 30, 2024 Operator: Hello, everyone, and thank you for joining us for Marti’s First Half 2024 Conference Call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results